Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Technology-Enhanced Acceleration of Germline Evaluation for Therapy - The TARGET Study

NCT04447703 is registered in ClinicalTrials.gov with Thomas Jefferson University as lead sponsor.

NCT NCT04447703
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04447703 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Technology-Enhanced Acceleration of Germline Evaluation for Therapy - The TARGET Study
Lead sponsor
Thomas Jefferson University
Phase
Not applicable
Overall status
Completed
Start date
August 27, 2020
Completion date
September 10, 2024
Enrollment
346 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

biochemically recurrent prostate carcinoma, metastatic prostate carcinoma, stage iiib prostate cancer ajcc v8, stage iiic prostate cancer ajcc v8, stage iv prostate cancer ajcc v8